ZEMANOVA, Milada, Robert PIRKER, Lubos PETRUZELKA, Zuzana ZBOŽÍNKOVÁ, Dragana JOVANOVIC, Mirjana RAJER, Krisztina BOGOS, Gunta PURKALNE, Vesna CERIMAN, Subhash CHAUDHARY, Igor RICHTER, Jiri KUFA, Lenka JAKUBÍKOVÁ, Marius ZEMAITIS, Marketa CERNOVSKA, Leona KOUBKOVA, Zdenka VILASOVA, Karin DIECKMANN, Attila FARKAS, Jelena SPASIC, Kateřina FRÖHLICH, Andreas TIEFENBACHER, Virag HOLLOSI, Juraj KULTAN, Iveta KOLAROVA a Jiri VOTRUBA. Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience. RADIOLOGY AND ONCOLOGY. Ljubljana: Association of Radiology and Oncology, 2020, roč. 54, č. 2, s. 209-220. ISSN 1318-2099. Dostupné z: https://dx.doi.org/10.2478/raon-2020-0026.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience
Autoři ZEMANOVA, Milada (203 Česká republika, garant), Robert PIRKER (40 Rakousko), Lubos PETRUZELKA (203 Česká republika), Zuzana ZBOŽÍNKOVÁ (203 Česká republika, domácí), Dragana JOVANOVIC (688 Srbsko), Mirjana RAJER (705 Slovinsko), Krisztina BOGOS (348 Maďarsko), Gunta PURKALNE (428 Lotyšsko), Vesna CERIMAN (688 Srbsko), Subhash CHAUDHARY (203 Česká republika), Igor RICHTER (203 Česká republika), Jiri KUFA (203 Česká republika), Lenka JAKUBÍKOVÁ (203 Česká republika, domácí), Marius ZEMAITIS (440 Litva), Marketa CERNOVSKA (203 Česká republika), Leona KOUBKOVA (203 Česká republika), Zdenka VILASOVA (203 Česká republika), Karin DIECKMANN (40 Rakousko), Attila FARKAS (348 Maďarsko), Jelena SPASIC (688 Srbsko), Kateřina FRÖHLICH (203 Česká republika, domácí), Andreas TIEFENBACHER (40 Rakousko), Virag HOLLOSI (348 Maďarsko), Juraj KULTAN (203 Česká republika), Iveta KOLAROVA (203 Česká republika) a Jiri VOTRUBA (203 Česká republika).
Vydání RADIOLOGY AND ONCOLOGY, Ljubljana, Association of Radiology and Oncology, 2020, 1318-2099.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Slovinsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.991
Kód RIV RIV/00216224:14110/20:00115905
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.2478/raon-2020-0026
UT WoS 000537450400008
Klíčová slova anglicky diagnostic procedures; multimodality treatment; non-small-cell lung cancer; stage III
Štítky 14110215, 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 3. 7. 2020 12:36.
Anotace
Background. Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the realworld setting in Central European countries to define areas for improvements. Patients and methods. This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Results. Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. Conclusions. The real-world study demonstrated a broad heterogeneity in the management of stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.
VytisknoutZobrazeno: 24. 7. 2024 11:22